Специфическое лечение астенических состояний: в фокусе сульбутиамин

1. Морозов П.В. Новое в лечение астении. Психиатрия и психофармакотерапия. 2005;3(7):154-9 [Morozov PV. New in the treatment of asthenia. Psychiatry and Ppsychopharmacotherapy. 2005;3(7):154-9 (in Russian)].
2. Чутко Л.С. Астенические расстройства в клинической практике. Медицинский совет. 2011;9-10:104-7 [Chutko LS. Asthenic disorders in clinical practice. Meditsinskiy sovet = Medical Council. 2011;9-10:104-107 (in Russian)].
3. Вахнина Н.В., Калимеева Е.Ю. Применение витаминно-минеральных комплексов в составе ноотропной терапии при астенических состояниях и неврологических расстройствах. Медицинский совет. 2015;11:12-6 [Vakhnina NV, Kalinicheva EYu. The use of vitamin and mineral complexes as part of nootropic therapy for asthenic conditions and neurological disorders. Meditsinskiy sovet = Medical Council. 2015;11:12-6 (in Russian)]. DOI:10.21518/2079-701X-2015-11-12-16
4. Петрова Н.Н., Морозов П.В., Маркин А.В., и др. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-CoV-2. Психиатрия и психофармакотерапия. 2020;6(22):8-24 [Petrova NN, Morozov PV, Markin AV, et al. The COVID-19 pandemic: current challenges of the time, as well as the latest data on the rational choice of psychopharmacotherapy in patients with SARS-CoV-2. Psychiatry and Psychopharmacotherapy. 2020;6(22):8-24 (in Russian)].
5. Воробьева А.А. Астенические состояния: эффективная и без­опасная терапия. Русский медицинский журнал. 2009;20(17):1330-3 [Vorobyeva AA. Asthenic conditions: effective and safe therapy. Russian Medical Journal. 2009;20(17):1330-3 (in Russian)].
6. Шакирова И.Н., Дюкова Г.М. Астения – междисциплинарная проблема. Трудный пациент. 2012;5(10):14-6 [Shakirova IN, Dyukova GM. Asthenia – an interdisciplinary problem. Trudnyj Pacient = Difficult Patient. 2012;5(10):14-6 (in Russian)].
7. Starling-Soares B, Carrera-Bastos P, Bettendorff L. Role of the synthetic B1 vitamin sulbutiamine on health. J Nutr Metab. 2020;2020:9349063. DOI:10.1155/2020/9349063
8. Филиппова А.В., Переверзев А.П., Эбзеева Е.Ю., Остроумова О.Д. Милдронат. Синдром хронической усталости. Медицинский алфавит. 2020;7:15-20 [Filippova AV, Pereverzev AP, Ebzeeva EYu, Ostroumova OD. Mildronat. Chronic fatigue syndrome. Medical Alphabet. 2020;7:15-20 (in Russian)]. DOI:10.33667/2078-5631-2020-7-15-20
9. Стаценко М.Е., Туркина С.В., Лопушкова Ю.Е. Новые данные о хорошо известном препарате: фокус на мельдоний. Медицинский совет. 2021;6(14):110-7 [Statsenko ME, Turkina SV, Pushkova YuE. New data on a well-known drug: focus on meldonium. Meditsinskiy sovet = Medical Council. 2021;6(14):110-7 (in Russian)]. 
DOI:10.21518/2079-701X-2021-14-110-117
10. Семак А.Е., Дымковская М.Н., Жарко А.Е., и др. Опыт использования и сравнительный анализ эффективности препаратов кавинтон и винпоцетин в лечении инфаркта мозга в раннем восстановительном периоде. Лечебное дело: научно-практический терапевтичес­кий журнал. 2014;5:7-14 [Semak AE, Dymkovskaya MN, Zharko AE, et al. Experience in the use and comparative analysis of the effectiveness of the drugs cavinton and vinpocetine in the treatment of cerebral infarction in the early recovery period. Medical Business: Scientific and Practical Therapeutic Journal. 2014;5:7-14 (in Russian)].
11. Чутко Л.С., Сурушкина С.Ю., Яковенко Е.А., и др. Возможности применения Цитофлавина при лечении когнитивных и эмоциональных нарушений у пациентов с головными болями напряжения. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019;11(119):32-6 [Chutko LS, Surushkina SYu, Yakovenko EA, et al. 
The possibilities of using Cytoflavin in the treatment of cognitive and emotional disorders in patients with tension headaches. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;11(119):32-6 (in Russian)]. DOI:10.17116/jnevro201911911132
12. Bettendorff L, Weekers L, Wins P, Schoffeniels E. Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem Pharmacol. 1990;40(11):2557-60. DOI:10.1016/0006-2952(90)90099-7
13. Bettendorff L, Wins P, Lesourd M. Subcellular localization and compartmentation of thiamine derivatives in rat brain. Biochim Biophys Acta – Mol Cell Res. 1994;1222(1):1-6. DOI:10.1016/0167-4889(94)90018-3
14. Micheau J, Durkin TP, Destrade C, et al. Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation. Pharmacol Biochem Behav. 1985;23(2):195-8. DOI:10.1016/0091-3057(85)90555-6
15. Михайлова Н.М. Применение Энериона для лечения астенических расстройств в психогериатрической практике. Психи­атрия. 2004;4(10):65-75 [Mikhailova NM. The use of Enerion for the treatment of asthenic disorders in psychogeriatric practice. Psychiatry. 2004;4(10):65-75 (in Russian)].
16. Trovero F, Gobbi M, Weil-Fuggaza J, et al. Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neurosci Lett. 2000;292(1):49-53. DOI:10.1016/s0304-3940(00)01420-8
17. Meltzer LT, Christoffersen CL, Serpa CA. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev. 1997;21(4):511-8.
DOI:10.1016/s0149-7634(96)00030-9
18. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 
19. Healy DJ, Meador-Woodruff JH. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res Mol Brain Res. 1997;47(1-2):331-8. DOI:10.1016/s0169-328x(97)00064-8 
20. Kwag J, Majid AS, Kang KD. Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons. Biol Pharm Bull. 2011;34(11):1759-64. DOI:10.1248/bpb.34.1759
21. Sevim S, Kaleağası H, Taşdelen B. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;16:40-3. DOI:10.1016/j.msard.2017.05.010 
22. Balzamo E, Vuilloncacciuttolo G. Facilitation de l’etat de veille d’un traitement semi-chronique par la sulbutiamine (Arcalion) chez Macaca mulatta. Rev d’ Electroencéphalographie Neurophysiol Clin. 1982;12(4):373-8. DOI:10.1016/s0370-4475(82)80029-4
23. Lôo H, Poirier MF, Ollat H, Elatki S. Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes. Encephale. 2000;26(2):70-5. 
24. Volvert ML, Seyen S, Piette M, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008;8(1):10. DOI:10.1186/1471-2210-8-10
25. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. Int J Mol Sci. 2021;22(11):5418. DOI:10.3390/ijms22115418
26. Головина А.Г. Энерион в терапии астенических расстройств у подростков в амбулаторной психиатрической практике. Психиатрия. 2004;3(9):43-9 [Golovina AG. Enerion in the treatment of asthenic disorders in adolescents in outpatient psychiatric practice. Psychiatry. 2004;3(9):43-9 (in Russian)].
27. Гурак С.В., Парфенов В.А. Астения после инсульта и инфаркта миокарда и ее лечение энерионом. Клиническая геронтология. 2005;8(11):9-12 [Gurak SV, Parfenov VA. Asthenia after stroke and myocardial infarction and its treatment with enerion. Clinical Gerontology. 2005;8(11):9-12 (in Russian)].
28. Ollat H, Laurent B, Bakchine S, et al. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease. Encephale. 2007;33(2):211-5. DOI:10.1016/s0013-7006(07)91552-3
29. Хасанова Д., Мухутдинова Э., Житкова Ю. Энерион (сульбутиамин) в лечении постинсультного астенического синдрома. Врач. 2008;7:66-9 [Khasanova D, Mukhutdinova E, Zhitkova Yu. Enerion (salbutyamine) in the treatment of post-stroke asthenic syndrome. Doctor. 2008;7:66-69 (in Russian)].
30. Лебедев М.А., Палатов С.Ю., Ковров Г.В. Усталость и ее проявления. Русский медицинский журнал. 2014;4(22):282-6 [Lebedev MA, Palatov SYu, Kovrov GV. Fatigue and its manifestations. Russian Medical Journal. 2014;4(22):282-286 (in Russian)].

________________________________________________

1. Morozov PV. New in the treatment of asthenia. Psychiatry and Ppsychopharmacotherapy. 2005;3(7):154-9 (in Russian).
2. Chutko LS. Asthenic disorders in clinical practice. Meditsinskiy sovet = Medical Council. 2011;9-10:104-107 (in Russian).
3. Vakhnina NV, Kalinicheva EYu. The use of vitamin and mineral complexes as part of nootropic therapy for asthenic conditions and neurological disorders. Meditsinskiy sovet = Medical Council. 2015;11:12-6 (in Russian). DOI:10.21518/2079-701X-2015-11-12-16
4. Petrova NN, Morozov PV, Markin AV, et al. The COVID-19 pandemic: current challenges of the time, as well as the latest data on the rational choice of psychopharmacotherapy in patients with SARS-CoV-2. Psychiatry and Psychopharmacotherapy. 2020;6(22):8-24 (in Russian).
5. Vorobyeva AA. Asthenic conditions: effective and safe therapy. Russian Medical Journal. 2009;20(17):1330-3 (in Russian).
6. Shakirova IN, Dyukova GM. Asthenia – an interdisciplinary problem. Trudnyj Pacient = Difficult Patient. 2012;5(10):14-6 (in Russian).
7. Starling-Soares B, Carrera-Bastos P, Bettendorff L. Role of the synthetic B1 vitamin sulbutiamine on health. J Nutr Metab. 2020;2020:9349063. DOI:10.1155/2020/9349063
8. Filippova AV, Pereverzev AP, Ebzeeva EYu, Ostroumova OD. Mildronat. Chronic fatigue syndrome. Medical Alphabet. 2020;7:15-20 (in Russian). DOI:10.33667/2078-5631-2020-7-15-20
9. Statsenko ME, Turkina SV, Pushkova YuE. New data on a well-known drug: focus on meldonium. Meditsinskiy sovet = Medical Council. 2021;6(14):110-7 (in Russian). 
DOI:10.21518/2079-701X-2021-14-110-117
10. Semak AE, Dymkovskaya MN, Zharko AE, et al. Experience in the use and comparative analysis of the effectiveness of the drugs cavinton and vinpocetine in the treatment of cerebral infarction in the early recovery period. Medical Business: Scientific and Practical Therapeutic Journal. 2014;5:7-14 (in Russian).
11. Chutko LS, Surushkina SYu, Yakovenko EA, et al. 
The possibilities of using Cytoflavin in the treatment of cognitive and emotional disorders in patients with tension headaches. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;11(119):32-6 (in Russian). DOI:10.17116/jnevro201911911132
12. Bettendorff L, Weekers L, Wins P, Schoffeniels E. Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem Pharmacol. 1990;40(11):2557-60. DOI:10.1016/0006-2952(90)90099-7
13. Bettendorff L, Wins P, Lesourd M. Subcellular localization and compartmentation of thiamine derivatives in rat brain. Biochim Biophys Acta – Mol Cell Res. 1994;1222(1):1-6. DOI:10.1016/0167-4889(94)90018-3
14. Micheau J, Durkin TP, Destrade C, et al. Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation. Pharmacol Biochem Behav. 1985;23(2):195-8. DOI:10.1016/0091-3057(85)90555-6
15. Mikhailova NM. The use of Enerion for the treatment of asthenic disorders in psychogeriatric practice. Psychiatry. 2004;4(10):65-75 (in Russian).
16. Trovero F, Gobbi M, Weil-Fuggaza J, et al. Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neurosci Lett. 2000;292(1):49-53. DOI:10.1016/s0304-3940(00)01420-8
17. Meltzer LT, Christoffersen CL, Serpa CA. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev. 1997;21(4):511-8.
DOI:10.1016/s0149-7634(96)00030-9
18. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 
19. Healy DJ, Meador-Woodruff JH. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res Mol Brain Res. 1997;47(1-2):331-8. DOI:10.1016/s0169-328x(97)00064-8 
20. Kwag J, Majid AS, Kang KD. Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons. Biol Pharm Bull. 2011;34(11):1759-64. DOI:10.1248/bpb.34.1759
21. Sevim S, Kaleağası H, Taşdelen B. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;16:40-3. DOI:10.1016/j.msard.2017.05.010 
22. Balzamo E, Vuilloncacciuttolo G. Facilitation de l’etat de veille d’un traitement semi-chronique par la sulbutiamine (Arcalion) chez Macaca mulatta. Rev d’ Electroencéphalographie Neurophysiol Clin. 1982;12(4):373-8. DOI:10.1016/s0370-4475(82)80029-4
23. Lôo H, Poirier MF, Ollat H, Elatki S. Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes. Encephale. 2000;26(2):70-5. 
24. Volvert ML, Seyen S, Piette M, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008;8(1):10. DOI:10.1186/1471-2210-8-10
25. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. Int J Mol Sci. 2021;22(11):5418. DOI:10.3390/ijms22115418
26. Golovina AG. Enerion in the treatment of asthenic disorders in adolescents in outpatient psychiatric practice. Psychiatry. 2004;3(9):43-9 (in Russian).
27. Gurak SV, Parfenov VA. Asthenia after stroke and myocardial infarction and its treatment with enerion. Clinical Gerontology. 2005;8(11):9-12 (in Russian).
28. Ollat H, Laurent B, Bakchine S, et al. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease. Encephale. 2007;33(2):211-5. DOI:10.1016/s0013-7006(07)91552-3
29. Khasanova D, Mukhutdinova E, Zhitkova Yu. Enerion (salbutyamine) in the treatment of post-stroke asthenic syndrome. Doctor. 2008;7:66-69 (in Russian).
30. Lebedev MA, Palatov SYu, Kovrov GV. Fatigue and its manifestations. Russian Medical Journal. 2014;4(22):282-286 (in Russian).

Ю.В. Быков*1, Р.А. Беккер2

1 ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России, Ставрополь, Россия;
2 Университет им. Давида Бен-Гуриона в Негеве, Беэр-Шева, Израиль
*yubykov@gmail.com

________________________________________________

Yuri V. Bykov*1, Roman A. Bekker2 

1 Stavropol State Medical University, Stavropol, Russia;
2 David Ben-Gurion University in Negev, Be’er-Sheva, Israel
*yubykov@gmail.com